Free Trial

JPMorgan Chase & Co.'s Rating of Kura Oncology on 10/1/2026

On October 1, 2026, JPMorgan Chase & Co. updated its outlook on Kura Oncology (NASDAQ:KURA) with the action "Initiated Coverage", setting a "Overweight" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from JPMorgan Chase & Co.

DateCompanyAction
10/14/2026
Moody's Corporation stock logo
MCO
Moody's
Lower Price Target
10/14/2026
MSCI Inc stock logo
MSCI
MSCI
Lower Price Target
10/14/2026
S&P Global Inc. stock logo
SPGI
S&P Global
Lower Price Target
10/14/2026
The Western Union Company stock logo
WU
Western Union
Lower Price Target
10/14/2026
Roblox Corporation stock logo
RBLX
Roblox
Boost Price Target
10/14/2026
Carpenter Technology Corporation stock logo
CRS
Carpenter Technology
Lower Price Target
More Ratings From JPMorgan Chase & Co.